Use of Oritavancin in Acute Bacterial Skin and Skin Structure Infections Patients Receiving Intravenous Antibiotics: A US Hospital Budget Impact Analysis.

Abstract

BACKGROUND AND OBJECTIVE:

Nearly 10% of all US hospital admissions are attributed to acute bacterial skin and skin structure infections (ABSSSIs). While most antibacterials used to treat these infections require multi-day and multi-dose regimens, a single-dose treatment is now available. The objective of this analysis is to estimate the annual budget impact of using single-dose oritavancin in patients with moderate to severe ABSSSIs receiving intravenous methicillin-resistant Staphylococcus aureus (MRSA)-active antibacterials from a US hospital perspective.

METHODS:

A decision-analytic model based on current clinical practice was developed to estimate the economic impact of oritavancin. Utilization of antibacterials and rates of hospital admission were derived from the Premier Research Database. Demographic and clinical data were informed by the published literature and 2014 wholesale drug acquisition costs were used. Other costs were based on the published literature and Medicare National Limitation amounts. All costs were inflated to 2014 US dollars. Two base-case scenarios were considered: one for hospitals with ambulatory services and one for hospitals without ambulatory services.

RESULTS:

For a US hospital with ambulatory services with 1000 ABSSSI patients receiving intravenous MRSA antibiotics annually, use of oritavancin in 26% of patients is estimated to reduce the total annual budget by 12.9% (US$1.23 million), or approximately US$1234.67 per patient. Total inpatient costs will be reduced by 22.3% (US$1.40 million) and outpatient costs will increase slightly by 1.7% (US$55,310). Pharmaceutical cost increases are offset by savings in the inpatient setting from fewer hospital admissions. Hospitals without ambulatory services are estimated to receive overall cost savings of 9.3% (US$0.63 million).

CONCLUSION:

Use of single-dose oritavancin in select ABSSSI patients with suspected or confirmed MRSA involvement is estimated to save US hospitals approximately 9.3-12.9% per year by reducing hospital admissions and lowering drug administration burden.

• Authors: Ivar S Jensen, Thomas P Lodise, Weihong Fan, Chining Wu, Philip L Cyr, David P Nicolau, Scott DuFour, Katherine A Sulham
• Journal: Clinical drug investigation (Clin Drug Investig) Vol. 36 Issue 2 Pg. 157-68 (Feb 2016) ISSN: 1179-1918 [Electronic] New Zealand
• PMID: 26692006 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Anti-Bacterial Agents
• Glycopeptides
• Lipoglycopeptides
• oritavancin

Topics

• Acute Disease
• Administration, Intravenous
• Ambulatory Care
• Anti-Bacterial Agents (economics, therapeutic use)
• Costs and Cost Analysis
• Decision Support Techniques
• Drug Costs
• Economics, Hospital
• Female
• Glycopeptides (economics, therapeutic use)
• Hospitalization
• Humans
• Lipoglycopeptides
• Male
• Methicillin-Resistant Staphylococcus aureus
• Models, Economic
• Skin Diseases, Bacterial (drug therapy, economics)
• Staphylococcal Infections (drug therapy, economics)